Granza Bio is a promising player in the biotechnology landscape, introducing a cutting-edge delivery platform that promises to revolutionize the field of therapeutic delivery. With their slogan, "Advancing Therapeutic Delivery using Precision Shells," the company is on a mission to enhance the specificity and effectiveness of therapeutic treatments.
Founded in 2023, Granza Bio is innovating by developing novel delivery "shells" to precisely direct therapeutic cargo to targeted tissues. Their leading technology harnesses the body's own immune "attack particles" to combat conditions such as cancer, autoimmune diseases, and infections, representing a significant leap forward in personalized medicine.
The company's potential was recognized in its recent Seed Round investment, raising $7.14M on 03 July 2024. This round was backed by notable investors including Felicis Ventures, Pioneer Fund, North South Ventures, and others, signaling strong confidence in Granza Bio's innovative approach and future prospects.
